Shiga toxin 2 is one of the toxin families investigated in Shiga toxin-producing E. coli (STEC). GI-MAP reports a genetic target called stx2. It is a finding to discuss promptly with a clinician, not a direct toxin measurement or a personal forecast of complications.
On this page
Why a positive stx2 finding deserves attention
STEC illness can include bloody diarrhea and severe cramps, and some infections are complicated by hemolytic uremic syndrome (HUS). HUS involves blood-cell changes and kidney injury that require medical assessment. A stool DNA result cannot diagnose that syndrome. [1]
stx2, stx1 and O157 answer different questions
stx1 and stx2 are separate toxin-gene targets. O157 is a typing marker. A negative O157 result does not exclude a non-O157 STEC organism; do not dismiss stx2 because another line is negative. The manufacturer’s EPEC/EHEC label also needs interpretation alongside the toxin findings. [2]
What GI-MAP cannot establish from stx2 alone
The result does not tell you the exact toxin subtype, whether toxin is being produced, or whether every detected E. coli target belongs to the same organism. It cannot replace confirmation when that would change treatment or public-health action.
Likewise, a low reported quantity is not a guarantee of low clinical risk, and an undetected target cannot explain continuing severe symptoms. The clinician may request further stool tests and assess blood count and kidney function when the illness warrants it.
Act on symptoms while arranging interpretation
Seek prompt care for bloody diarrhea, and urgent care for reduced urination, faintness, unusual bruising or severe weakness. Avoid starting leftover antibiotics or anti-diarrheal medicines for a possible STEC illness without medical advice. CDC guidance highlights the potential for complications with inappropriate treatment. [1]
Common questions
Does stx2-positive mean I will develop HUS?
No. It identifies a laboratory finding relevant to the assessment. Many factors influence clinical outcome, and the result is not a probability calculation.
Should I repeat GI-MAP to see whether the number falls?
Do not use a repeat mail-in panel to delay care or judge recovery yourself. Ask the treating clinician which follow-up, if any, serves the clinical question.
Sources and review
Sources checked October 7, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- CDC: Information for clinicians about E. coli
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
Medical review of this article is pending. For a correction or source question, contact GI MAP Test.